Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

Can You Live Longer Than 5 Years With ALS? Life Expectancy

At a Glance

Yes, it is possible to live longer than 5 years with ALS. While the average life expectancy is 2 to 5 years, about 20% of people live 5 years or longer. Care at a multidisciplinary ALS clinic, breathing support, feeding tubes, and medications can help extend survival and improve quality of life.

Yes, it is entirely possible to live longer than 5 years with amyotrophic lateral sclerosis (ALS). While the average life expectancy after diagnosis is often cited as 2 to 5 years, this statistic is only an average. The disease affects everyone differently, and a significant portion of people surpass this timeframe: about 20% of people live for 5 years or longer, and up to 10% live for 10 years or more [1][2].

Factors That Influence Survival

Every person’s journey with ALS is unique, and several factors can influence how quickly the disease progresses. People who experience their first symptoms in their arms or legs (known as limb-onset ALS) often experience slower progression compared to those whose first symptoms affect speech or swallowing (bulbar-onset ALS) [2][3].

Younger age at onset and certain genetic markers—such as the SOD1 mutation—can also play a role in the course of the disease [2][4]. Because some mutations can run in families, your doctor may suggest genetic counseling or testing to help you understand the specific nature of your ALS and whether it carries implications for your relatives.

Interventions That Can Extend Life and Improve Quality

Advances in care have made a real difference in how ALS is managed. Engaging in proactive symptom management is one of the most effective ways to improve both survival length and your day-to-day quality of life [1].

Multidisciplinary ALS Clinics

The most impactful step you can take is receiving care at a specialized multidisciplinary ALS clinic. Research shows that patients who attend these clinics have improved survival and better symptom control compared to those who receive standard care [1][5]. In these clinics, a team of specialists—including neurologists, respiratory therapists, dietitians, and physical therapists—work together to anticipate your needs and adjust your care plan as the disease changes [6]. You can locate these specialized teams by searching for “Certified Treatment Centers of Excellence” through the ALS Association or finding an “MDA Care Center” through the Muscular Dystrophy Association.

Disease-Modifying Medications

In addition to supportive care, there are FDA-approved medications designed to modify the progression of the disease. Riluzole, the longest-standing treatment, has been clinically proven to extend median survival by a few months [7][8]. Other medications, such as edaravone, may help slow the rate of physical functional decline in some patients [7][9]. Furthermore, new targeted therapies are becoming available for specific genetic forms of the disease. Discussing these medications early with your neurologist is a critical part of building a comprehensive care plan.

Respiratory Support (Non-Invasive Ventilation)

As ALS affects the muscles involved in breathing, you may eventually need support to breathe comfortably, especially at night. Non-invasive ventilation (NIV)—often delivered via a BiPAP machine (bilevel positive airway pressure) through a mask—is a crucial intervention. NIV helps manage breathlessness, significantly improves sleep quality, and plays a key role in extending survival and enhancing daily comfort [10][11][6].

Nutritional Support (PEG Tubes)

Proper nutrition is vital in ALS, but swallowing difficulties can make eating challenging and dangerous due to the risk of choking or inhaling food (aspiration). A percutaneous endoscopic gastrostomy (PEG) tube is a feeding tube placed directly into the stomach. Getting a PEG tube early, before significant weight loss or severe breathing problems occur, ensures you receive adequate nutrition and hydration safely [12]. While the procedure is generally safe, timing is critical: waiting until lung function is severely reduced can increase surgical risks [13][14].

Focusing on the Future

While ALS is a progressive and serious disease, the initial 2-to-5-year average is a starting point for understanding, not an absolute rule. Taking a proactive approach—whether through medications, early respiratory and nutritional support, or simply asking about voice banking and mental health resources early on—can significantly improve your journey. By working with a dedicated care team, many patients continue to live meaningful lives well past the five-year mark.

Common questions in this guide

Does everyone with ALS pass away within 5 years?
No. While the average life expectancy is 2 to 5 years, about 20% of people with ALS live for 5 years or longer, and up to 10% live for 10 years or more. Every person's journey with the disease is unique.
What factors can slow down ALS progression?
Disease progression is often slower in people who are younger at diagnosis or whose first symptoms begin in their arms or legs (limb-onset ALS). Certain genetic factors can also influence how quickly the disease progresses.
How does a BiPAP machine help someone with ALS?
A BiPAP machine provides non-invasive ventilation to support weakened breathing muscles, especially at night. This intervention helps manage breathlessness, improves sleep quality, and can significantly extend survival and daily comfort.
When should an ALS patient consider getting a feeding tube?
It is recommended to get a PEG feeding tube early, before experiencing significant weight loss or severe breathing difficulties. Waiting until lung function is severely reduced can make the placement procedure riskier.
Are there medications that can extend life for ALS patients?
Yes, FDA-approved medications like riluzole have been clinically proven to extend median survival. Other drugs like edaravone can help slow the rate of physical decline, and new targeted therapies are available for specific genetic forms of the disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my baseline breathing function (forced vital capacity), and how often will we measure it?
  2. 2.Am I a candidate for disease-modifying ALS medications like riluzole or edaravone?
  3. 3.What are my options for genetic testing or counseling to understand if my ALS has a familial component?
  4. 4.When should we schedule a swallow study to monitor my risk of aspiration?
  5. 5.At what point in my progression should we start discussing a feeding tube (PEG) or non-invasive ventilation (BiPAP)?
  6. 6.Can you refer me to a certified multidisciplinary ALS clinic, or do you coordinate with one?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Canadian best practice recommendations for the management of amyotrophic lateral sclerosis.

    Shoesmith C, Abrahao A, Benstead T, et al.

    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2020; (192(46)):E1453-E1468 doi:10.1503/cmaj.191721.

    PMID: 33199452
  2. 2

    Intermediate Repeat Expansion in the ATXN2 Gene as a Risk Factor in the ALS and FTD Spanish Population.

    Borrego-Hernández D, Vázquez-Costa JF, Domínguez-Rubio R, et al.

    Biomedicines 2024; (12(2)) doi:10.3390/biomedicines12020356.

    PMID: 38397958
  3. 3

    Prevalence and impact of comorbidities in amyotrophic lateral sclerosis.

    Jellinger KA

    Journal of neural transmission (Vienna, Austria : 1996) 2026; (133(3)):379-396 doi:10.1007/s00702-025-02971-7.

    PMID: 40515812
  4. 4

    OSMR is a potential driver of inflammation in amyotrophic lateral sclerosis.

    Chen W, Jiang S, Li S, et al.

    Neural regeneration research 2024; (19(11)):2513-2521 doi:10.4103/1673-5374.391309.

    PMID: 38526287
  5. 5

    Multidisciplinary care in Amyotrophic Lateral Sclerosis: a systematic review and meta-analysis.

    de Almeida FEO, do Carmo Santana AK, de Carvalho FO

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(3)):911-923 doi:10.1007/s10072-020-05011-2.

    PMID: 33443670
  6. 6

    [Amyotrophic lateral sclerosis (ALS) - diagnosis, course of disease and treatment options].

    Meyer T

    Deutsche medizinische Wochenschrift (1946) 2021; (146(24-25)):1613-1618 doi:10.1055/a-1562-7882.

    PMID: 34879411
  7. 7

    Amyotrophic Lateral Sclerosis: An Update for 2018.

    Oskarsson B, Gendron TF, Staff NP

    Mayo Clinic proceedings 2018; (93(11)):1617-1628 doi:10.1016/j.mayocp.2018.04.007.

    PMID: 30401437
  8. 8

    Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.

    Lu H, Le WD, Xie YY, Wang XP

    Current neuropharmacology 2016; (14(4)):314-21 doi:10.2174/1570159x14666160120152423.

    PMID: 26786249
  9. 9

    Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).

    Shefner J, Heiman-Patterson T, Pioro EP, et al.

    Muscle & nerve 2020; (61(2)):218-221 doi:10.1002/mus.26740.

    PMID: 31621933
  10. 10

    Optimizing breathlessness management in amyotrophic lateral sclerosis: insights from a comprehensive systematic review.

    Filipe CB, Carreira NR, Reis-Pina P

    BMC palliative care 2024; (23(1)):100 doi:10.1186/s12904-024-01429-z.

    PMID: 38622643
  11. 11

    Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases.

    Izenberg A

    Continuum (Minneapolis, Minn.) 2023; (29(5)):1538-1563 doi:10.1212/CON.0000000000001345.

    PMID: 37851042
  12. 12

    Outcomes after intervention for enteral nutrition in patients with amyotrophic lateral sclerosis in multidisciplinary clinics.

    Fullam T, Hunt SL, Han M, et al.

    Muscle & nerve 2024; (70(1)):94-100 doi:10.1002/mus.28103.

    PMID: 38695638
  13. 13

    Gastrostomy placement in patients with amyotrophic lateral sclerosis: assessment of risk factors for post-procedural respiratory failure.

    An TJ, Jang S, Hering K, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2024; (25(7-8)):680-686 doi:10.1080/21678421.2024.2384994.

    PMID: 39086006
  14. 14

    Predictive factors for prognosis after gastrostomy placement in routine non-invasive ventilation users ALS patients.

    Hesters A, Amador MDM, Debs R, et al.

    Scientific reports 2020; (10(1)):15117 doi:10.1038/s41598-020-70422-2.

    PMID: 32934263

This page provides information about ALS survival rates and management for educational purposes only. Always consult your neurologist or ALS care team for medical advice regarding your prognosis and treatment plan.

Get notified when new evidence is published on Amyotrophic lateral sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.